Chris Boshoff: FDA Approves Our Treatment for Hemophilia A and B for 2 New Patient Populations
Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared on LinkedIn:
”The FDA has approved our treatment for hemophilia A and B for two new patient populations following a priority review.
With this approval, children ages 6 to 11 with hemophilia B will have a subcutaneous, non-factor treatment option available for the first time.
Bringing a medicine discovered and developed by Pfizer to the people who need it most—guided at every step by patient need—is an important moment for our teams.
A special thank you to the Pfizer scientists who are continuing to advance care for people with hemophilia, and to the hemophilia patient community who participated in clinical trials that are instrumental to making advancements like this one happen.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines